Migraine
Conditions
Brief summary
- Response or non-response to rimegepant 75 mg or 2x75 mg expressed as percentage in pain freedom or freedom from the most bothersome migraine-associated symptom apart from headache after 2 hours (reported in questionnaire)
Detailed description
- Freedom from photophobia, phonophobia, nausea and pain relief 2 hours after administration of rimegepant in either 75 mg or 2x75 mg during a moderate to severe migraine episode; probability of using rescue medication within 24 hours after the dose; sustained freedom from pain, sustained pain relief, pain relapse 2 hours to 48 hours after the dose - Blood: sex steroid levels, rimegepant concentration, CGRP. parameters: Total body weight, total body water (TBW), free mass (FFM), fat mass (FM), s
Interventions
Sponsors
Konvent Der Barmherzigen Brueder
Eligibility
Sex/Gender
All
Age
18 Years to 64 Years
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| - Response or non-response to rimegepant 75 mg or 2x75 mg expressed as percentage in pain freedom or freedom from the most bothersome migraine-associated symptom apart from headache after 2 hours (reported in questionnaire) | — |
Secondary
| Measure | Time frame |
|---|---|
| - Freedom from photophobia, phonophobia, nausea and pain relief 2 hours after administration of rimegepant in either 75 mg or 2x75 mg during a moderate to severe migraine episode; probability of using rescue medication within 24 hours after the dose; sustained freedom from pain, sustained pain relief, pain relapse 2 hours to 48 hours after the dose - Blood: sex steroid levels, rimegepant concentration, CGRP. parameters: Total body weight, total body water (TBW), free mass (FFM), fat mass (FM), s | — |
Outcome results
None listed